The New Zealand medical journal
-
Review Meta Analysis
Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis.
To determine the risk of serious cardiovascular events associated with the use of the COX-2 inhibitor valdecoxib and its prodrug parecoxib following major surgery. ⋯ There is an increased cardiovascular risk associated with parecoxib/valdecoxib therapy in the post-surgical situation. These findings are consistent with a class effect for COX-2 inhibitors increasing the risk of cardiovascular events.